Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1191-1200

  Knowles, Sandra R ^a   Drucker, Aaron M ^a   Weber, Elizabeth A ^a   Shear, Neil H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Aspirin; Asthma; Desensitization; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LUMIRACOXIB; MELOXICAM; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRANLUKAST; ROFECOXIB; SALSALATE; SULINDAC; TACROLIMUS; TOLMETIN; ZAFIRLUKAST; ZILEUTON; ZOMEPIRAC;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CROSS REACTION; DESENSITIZATION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME INHIBITION; EVALUATION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; PUBLICATION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINORRHEA; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT INDICATION; URTICARIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 34547228679     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K023     Document Type: Review

References (92)

1. Stevenson D. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24:491-505. DOI 10.1016/j.iac.2004.03.001
2. Sanchez-Borges M, Capriles-Hulett A, Caballero M. The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity. J Investig Allergol Clin Immunol 2004;14:329-34.
3. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980;35:149-54.
4. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434. DOI 10.1136/bmj.328.7437.434
5. Stevenson D, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallele reactions to drugs that inhibit cyclo-oxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:1-4.
6. Gollapudi R, Teeirstein P, Stevenson D, Simon R. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004;292:3017-23. DOI 10.1001/jama.292.24.3017
7. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21. DOI 10.1067/mai.2003.1487
8. Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Int Med J 2005;35:240-6.
9. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002;57:569-74.
10. Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003;58:1064-6.
11. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22.
12. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-5. DOI 10.1016/j.jaci.2005.08.035
13. Yoshimine F, Hasegawa T, Suzuki E, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005;10:477-84.
14. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6.
15. Schiavino D, Nucera E, Milani A, et al. The aspirin disease. Thorax 2000;55(suppl 2):S66-9.
16. Hamad A, Sutcliffe A, Knox A. Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 2004;64:2417-32.
17. Rosado A, Vives R, Gonzalez R, Rodriguez J. Can NSAIDs intolerance disappear? A study of three cases. Allergy 2003;58:689-90.
18. Body R, Potier K. Best evidence topic report. Non-steroidal anti-inflammatory drugs and exacerbations of asthma in children. Emerg Med J 2004;21:713-4.
19. Grattan C. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003;28:123-7.
20. Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Reports 2005;5:277-83.
21. Szczeklik A, Sanak M. The broken balance in aspirin hypersensitivity. Eur J Pharmacol 2006;533:145-55. DOI 10.1016/j.ejphar.2005.12.053
22. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:1095-8.
23. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004;113:771-5. DOI 10.1016/j.jaci.2003.12.323
24. Kim S, Ye Y, Lee S, Park H. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol 2006;6:266-70.
25. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
26. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001;31:1607-14.
27. Wedi B, Kapp A. Aspirin induced adverse skin reactions: new pathophysiological aspects. Thorax 2000;55(suppl 2):S70-1.
28. Bochenek G, Niz Ankowska E, Szczeklik A. Testing for aspirin hypersensitivity. Allergy 2002;57:562-5.
29. Jawien J. A new insight into aspirin-induced asthma. Eur J Clin Invest 2002;32:134-8.
30. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal antiinflammatory drugs. Arch Dermatol 2003;139:1577-82.
31. Melillo G, Balzano G, Bianco S, et al. Report of the INTERASMA Working Group on Standardization of Inhalation Provocation Tests in Aspirin-Induced Asthma. Oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy 2001;56:899-911.
32. Stevenson D, Woessner K, Simon R, Namazy J. Evidence-based protocols for oral NSAID challenges. J Pediatr 2006;148:704-5. DOI 10.1016/j.jpeds.2005.12.023
33. Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 2000;55(suppl 2):S42-4.
34. Mathison D, Stevenson D. Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges. J Allergy Clin Immunol 1979;64:669-74.
35. Sousa A, Parikh A, Scadding G, Corrigan C, Lee T. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-9.
36. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982;69:11-9.
37. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003;90:338-41.
38. Stevenson D, Hankammer M, Mathison D, Christiansen S, Simon R. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996;98:751-8.
39. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-6.
40. Lee J, Simon R, Stevenson D. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-64. DOI 10.1016/j.jaci.2006.09.011
41. Mardiney M, Borish L. Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad (letter). Arch Otolaryngol Head Neck Surg 2001;127:1287.
42. Gosepath J, Schaefer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg 2001;127:316-21.
43. Macy E, Bernstein J, Castells M, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007;98:172-4.
44. Babu K, Savli S. Aspirin and asthma. Chest 2000;118:1470-6.
45. Berges-Gimeno MP, Stevenson DD. Nonsteroidal anti-inflammatory drug-induced reactions and desensitization. J Asthma 2004;41:375-84.
46. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005;95:509-10.
47. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria- angioedema. J Allergy Clin Immunol 2000;105:997-1001.
48. Page NA, Schroeder WS. Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Ann Pharmacother 2007;41:61-7. Epub 2 Jan 2007. DOI 10.1345/aph.1H437
49. Asad SI, Kemeny DM, Youlten U, Frankland AW, Lessof MH. Effect of aspirin in "aspirin sensitive" patients. Br Med J (Clin Res Ed) 1984;288:745-8.
50. Grzelewska-Rzymowska I, Roznlecki J, Szmidt M. Aspirin desensitization in patients with aspirin-induced urticaria and angioedema. Allerg Immunol (Paris) 1988;16:305-8.
51. Stevenson DD, Simon RA. Sensitivity to aspirin and non-steroidal antiinflammatory drugs. In: Middleton EJ, Reed CE, Ellis EF, et al., eds. Allergy: principles and practice. 2 vol. St. Louis: Mosby, 1993:1747-65.
52. Volkman JA, Pontikes PJ. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann Pharmacother 2002;36: 1457-61. DOI 10.1345/aph.1A151
53. Stevenson D, Simon R, Mathison D, Christiansen SC. Montelukast is only partially effective in inhibiting aspiring responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000;85:477-82.
54. Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004;24:226-30.
55. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004;59:289-94.
56. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002;32:1491-6.
57. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;95:330-5.
58. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
59. Yoshida S, Sakamoto H, Ishizaki Y, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000;30:64-70.
60. Perez C, Sanchez-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID -induced urticaria and angioedema. J Allergy Clin Immunol 2001;106:1060-1.
61. Asero R. Leukotriene receptor antagonists may prevent NSAID -induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000;85:156-7.
62. Serrano C, Valero A, Picado C. Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: a case report. J Investig Allergol Clin Immunol 2005;15:156-7.
63. Matsuo N, Shimoda T, Mitsuta K, et al. Tacrolimus inhibits cytokine production and chemical mediator release following antigen stimulation of passively sensitized human lung tissues. Ann Allergy Asthma Immunol 2001;86:671-8.
64. Kawano T, Matsuse H, Kondo Y, et al. Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin. J Allergy Clin Immunol 2004;114:1278-81.
65. Stevenson DD, Mehra PK, White AA, Gupta S, Woessner KM, Simon RA. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2005;116:755-60. DOI 10.1016/j.jaci.2005.05.020
66. Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002;57(suppl 72):58-60.
67. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004;41:67-75.
68. West PM, Fernandez C. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Ann Pharmacother 2003;37:1497-501. DOI 10.1345/aph.1C497
69. Prieto A, De Barrio M, Martin E, et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. J Allergy Clin Immunol 2007;119:960-4. DOI 10.1016/j.jaci.2006.12.616
70. Szczeklik A, Nizankowska A, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-25.
71. Martin-Garcia C, Hinojosa M, Beiges P, et al. Safety of cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-7.
72. Woessner K, Simon R, Stevenson D. The safety of celecoxib in patients with aspiring-sensitive asthma. Arth Rheum 2002;46:2201-6.
73. Stevenson D, Simon R. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
74. Perrone M, Artesani M, Viola M, et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003;132:82-6.
75. Senna G, Bilo M, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Ann Allergy Clin Immunol 2004;36:215-8.
76. Celik G, Pasaoglu G, Bavbek S, et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 2005;42:127-31.
77. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004;93:339-44.
78. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-21. DOI 10.1067/mai.2003.1450
79. Micheletto C, Tognella S, Guerriero M, Dal Negro R. Nasal and bronchial tolerability of rofecoxib in patients with aspirin induced asthma. Allerg Immunol (Paris) 2006;38:10-4.
80. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodrigue R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003;13:20-5.
81. Baldassarre S, Schandene L, Choufani G, Michils A. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol 2006;117:215-7.
82. Passero M, Chowdhry S. Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma. Chest 2003;123:2155-6.
83. Sanchez-Borges M, Capriles E, Caballero M. Adverse reactions to selective cyclooxygenase-2 inhibitors (coxibs). Am J Therapeut 2004;11:494-500.
84. Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005;95:438-42.
85. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with non-steroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154-8.
86. Liccardi G, Cazzola M, De Giglio C, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2005;15:249-53.
87. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005;94:34-8.
88. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005;94:29-33.
89. Kis B, Snipes J, Busija D. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions and uncertainties. J Pharmacol Exp Ther 2005;315:1-7.
90. Settipane R, Schrank P, Simon R, Mathieson D, Christiansen S, Stevenson D. Prevalence of cross sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-5.
91. Stevenson D, Hougham A, Shrank P, Goldlust B, Wilson R. Disalcid cross-sensitivity in aspirin sensitive asthmatics. J Allergy Clin Immunol 1990;86:749-58.
92. Szczeklik A, Nizankowska E, Dworski R. Choline magnesium trisalicylate in patients with aspirin-induced asthma. Eur Respir J 1990;3:535-9.